First international meeting on mycophenolate mofetil: An advance in the treatment of lupus 27 April 2004, St Thomas' Hospital, London, UK

Lupus

Volumn 13, Issue 7, 2004, Pages 543-545

  Vasoo, Sheila ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

CLINICAL TRIAL; CONFERENCE PAPER; DEATH; DEPRESSION; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; KIDNEY FAILURE; LUPUS ERYTHEMATOSUS NEPHRITIS; MORTALITY; NAUSEA; NEOPLASM; OVARY INSUFFICIENCY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED KINGDOM; VOMITING;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYCOPHENOLIC ACID;

EID: 4043071964     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu1086xx     Document Type: Conference Paper

References (21)

1. Contreras G, Roth D, Pardo V, Striker LG, Schultz DR. Lupus nephritis: a clinical review for practicing nephrologists. Clin Nephrol 2002; 57: 95-107.
2. Karim Y, D'Cruz DP. The NIH pulse cyclophosphamide regime: the end of an era? Lupus 2004; 13: 1-3.
3. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
4. Austin HA 3rd, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
5. Boumpas DT, Austin HA 3rd, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
6. Gourley MF, Austin HA 3rd, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-575.
7. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
8. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208.
9. El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003; 12: 692-696.
10. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
11. Fraenkel L, Bogardus S, Concato J. Patient preferences for treatment of lupus nephritis. Arthritis Rheum 2002; 47: 421-428.
12. Houssiau FA, D'Cruz DP, Haga HJ, Hughes GR. Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus 1991; 1: 31-35.
13. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997; 56: 481-487.
14. Haga HJ, D'Cruz D, Asherson R, Hughes GR. Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 1992; 51: 885-888.
15. Ioannidis JP, Boki KA, Katsorida ME. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258-264.
16. Ginzler EM, Aranow C, Buyon J. A multicenter study of mycophenolate mophetil (MMF) vs. intravenous cyclophosphamide (CYC) as induction therapy for severe lupus nephritis (LN): preliminary results. Arthritis Rheum 2003; 48: S1690.
17. Ginzler EM, Aranow C, Merrill JT, Orloff K, Henry D. Toxicity and tolerability of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (CYC) in a multicenter trial as induction therapy for lupus nephritis (LN). Arthritis Rheum 2003; 48: S1515.
18. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
19. Ferro ML, Karim MY, Abbs IC, D'Cruz D, Khamashta MA, Hughes GRV. Mycophenolate mofetil: a potential treatment for reducing proteinuria associated with membranous lupus nephritis. Arthritis Rheum 2003; 48: S1520.
20. Karim MY, Alba P, Cuadrado MJ et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002; 41: 876-882.
21. Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003; 62: 534-539.